Method for determining the risk of cancers in women, who are the carriers of mutation in gene BRCA1 and BRCA2 in relation to concentration of arsenic, cadmium, zinc and/or selenium in the blood

摘要

the object of the application is the method to determine the risk cancer in women carrying mutations in the brca1 gene, which is the founding / 2 typical for the population of poland, characterized by that,that includes the determination of the concentration of element selected from among arsenic, cadmium, zinc, selenium or selenium concentration ratio to arsenic in biological sample derived from the patient.with certain concentration indicates a significantly reduced risk of cancer development: in the event of low concentration arsenic in blood, especially below 0.65 mcg / l,the development of cancer in the case of low values for the concentration of cadmium in blood, especially below 0.32 mcg / l, the development of cancer in the presence of low concentrations of cadmium in the bloodespecially below 0.32 mcg / l, especially in patients below 50 r.ż.the non food supplements, cancer development in the event of an optimal concentration of zinc in the blood, especially in the field of 6300,00 to 6700,00 mcg / l,the development of cancer among women below 50 years of age, in the presence of an optimal concentration in the blood, especially in the range from 70 mcg / l to 89 micrograms / l, the development of cancer among women above 50 years of age,in the presence of optimal concentrations of selenium in the blood, especially in the range from 95 mcg / l for 120 mcg / l,the development of cancer in the presence of an optimal concentration ratio of selenium to the arsenic in the blood, especially in the field of 115,00 to 200,00,the patient should be examined population of poland and is carrying a mutation in brca1 / 2 gene selected among: 5382insc, c61g, 4153dela.